Category: Tocilizumab

Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies

Posted on | Posted on John Murphy | Leave a Comment on Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies

Suo-wen Xu, Iqra Ilyas & Jian-ping Weng Acta Pharmacologica Sinica volume 44, pages695–709 (2023) Nature Abstract The fight against coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is still raging. However, the pathophysiology of acute and post-acute manifestations of COVID-19 (long COVID-19) is understudied. Endothelial cells are sentinels lining the innermost layer of blood vessel that gatekeep micro- and macro-vascular health by […]

Different SARS-CoV-2 variants may give rise to different long COVID symptoms, study suggests

Posted on | Posted on John Murphy | Leave a Comment on Different SARS-CoV-2 variants may give rise to different long COVID symptoms, study suggests

Italian study of long-COVID patients suggests those infected with the Alpha variant experienced different neurological and emotional symptoms compared to those who contracted the original form of SARS-CoV-2 Authors: EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES 24-MAR-2022 New research to be presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) […]